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Antibiotic adjuvants from Buxus sempervirens to promote 
effective treatment of drug-resistant Staphylococcus aureus 
biofilms  
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1
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1
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c
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Plants have been long scrutinized in the quest for new antibiotics, but no strong antibiotic molecule was ever found. 
Evidences exist that most phytochemicals have a regulatory or adjuvant effect on other antibacterial compounds, thus 
promoting a greater therapeutic effect. The current study assessed twenty-eight plants from different families for their 
antibacterial activity and as adjuvants in antibiotic therapy against Staphylococcus aureus, including methicillin-resistant S. 
aureus (MRSA). Eucalyptus globulus, Castanea sativa, Agrimonia eupatoria and Fraxinus excelsior methanolic extracts 
showed antibacterial activity with minimal inhibitory concentrations (MICs) of 0.125-0.5, 0.5-1.0, 1.0-2.0, and 2.0-4.0 g L
-1
, 
respectively. Non-antibacterial plants were assessed in combination with ampicillin, oxacillin, ciprofloxacin, erythromycin 
and tetracycline by a modified disc diffusion test. Methanolic extracts of Acacia dealbata, Prunus spp. plants, Centaurea 
nigra, Eupatorium cannabium and Buxus sempervirens showed a potentiating effect mostly of ciprofloxacin, erythromycin 
and tetracycline. B. sempervirens was selected for its potentiating activity and applied against S. aureus biofilms. B. 
sempervirens (1 g L
-1
) was able to cause an 88% reduction of S. aureus within 1 h exposure. Further phytochemical 
investigation of B. sempervirens allowed to identify betulinic acid as a major component, together with other 
triterpenoids. Betulinic acid and other common terpernoids - lupeol, betulin, hederagenin, ursolic acid and oleanolic acid, 
were tested for antibacterial and antibiotic-potentiating activities. Among the tested compounds, oleanolic acid and 
ursolic acid - were highlighted, showing MIC of 62.5 and 15.6 mg L
-1
, respectively, against S. aureus. Additionally, oleanolic 
acid showed synergism when combined with tetracycline and erythromycin and caused biofilm reductions of 70, 81 and 
85% when applied at ½ MIC, MIC and 2 × MIC, respectively.
Introduction 
Two major circumstances have accentuated the quest for new 
antibacterial agents and alternative therapies in the last 
decades. Primarily, because microbes, due to their incredible 
and innate adaptability, seem to have at least equal chances 
for survival as scientists and pharmaceutical industries develop 
methods to kill them.
3
 Multidrug-resistant (MDR) bacteria are 
responsible for a large number of nosocomial but also 
community-acquired infections and are spreading all over the 
globe.
4
 Additionally, the limitation of our current arsenal of 
effective antibiotics accompanied by the lack of new 
antimicrobial alternatives are prompting the beginning of the 
“post-antibiotic era”, which threats all the achievements of 
modern medicine.  
Since the beginning of mankind plants were undoubtedly 
the most important source of therapeutic remedies with an 
enormous range of applications. The earliest records of natural 
products were depicted from Mesopotamia (2600 B.C.) and 
included oils from cypress (Cupressus sempervirens) and myrrh 
(Commiphora species), which are still used today to treat 
coughs, colds and inflammation.
5
 Many plant extracts and 
their phytochemical constituents are known to have 
antimicrobial activities.
6
 However, it can be rapidly established 
that this effort of finding individual active antibiotics in plants 
has been difficult, since the spectrum of activity of purified 
components is often non-specific (thus toxic) or very narrow, 
and for sure weaker than compounds from other sources such 
as fungi and bacteria.
7
 However, plants can still fight most of 
their infections successfully, which proves that plant defence 
mechanisms are still not well understood.  
Plants have faced most of their natural enemies for 
millions of years which allowed them to co-evolve and learn 
how to survive to their attacks.
8
 In fact, they do not produce 
single strong antibacterial compounds as their main defence 
mechanism, but hundreds of structurally different chemicals 
with a wide range of activity.
4
 Some of them are antimicrobial 
and act synergistically between each other to produce an 
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enhanced effect against the pathogen. Others are non-
antimicrobials, but can improve solubility, absorption and 
stability of the active compounds. At last but not least, some 
phytochemicals have been associated with an antibiotic 
adjuvant activity, especially due to the inhibition of the 
resistance mechanisms from plant pathogens. Efflux pump 
inhibitors (EPI) produced by plants have been extensively 
found and reported,
9-12
 as well as inhibitors of PBP2a; such as 
baicalein, tellimagrandin I, rugosin B and corilagin,
9, 13, 14
 
among others. The inhibition of the pathogen resistance 
mechanisms is a strategy already implemented in clinic. 
Clavulanic acid, which inhibits β-lactamases despite its weak 
antibacterial activity, combined with amoxicillin has proven to 
be remarkably effective in controlling a wide range of bacterial 
infections for two decades.
15
 Plants offer an untapped source 
of such adjuvant compounds. The aim of this study was first to 
evaluate the ability of a considerable range of different plants 
belonging to different families (in order to generate chemical 
variation) for their antibacterial activity against S. aureus 
strains, including efflux pump overexpressing and MRSA 
strains. The plants showing no detectable antibacterial activity 
were then assessed for their antibiotic-potentiation ability 
with five antibiotics. The antibiotics chosen (ampicillin and 
oxacillin - β-lactam, ciprofloxacin – fluoroquinolone, 
erythromycin – macrolide, and tetracycline) have more limited 
application nowadays due to increased bacterial tolerance. 
Additionally, since many reports have shown that 
staphylococcal infections were associated with biofilm 
formation, the biofilm control activity promoted by one 
promising plant extract, which was highlighted among the 
plants species selected, was evaluated as well. 
Materials and methods 
Plant material 
Twenty-eight Portuguese medicinal, invasive and fruit plant 
species were mostly collected in the region of Trás-os-Montes 
and Beira Transmontana (Portugal) and characterized by the 
Botanical Garden from Vila Real (Portugal), (Table 1). The 
leaves of all plants were harvested, separated and immediately 
frozen in liquid N2 in order to avoid unwanted enzymatic 
reactions and stored at -20 
o
C until analysis.  
 
Plant samples preparation and extraction procedure 
The plant materials (5 g) were freeze-dried and extracted with 
50 mL of MeOH at 30 
o
C, stirring at 150 rpm for 60 min. The 
samples were filtrated and re-extracted with 50 mL MeOH for 
60 min. The resulting extracts were combined and the solvent 
was evaporated at low temperature (< 40 ºC) under reduced 
pressure. The dried MeOH extracts were stored at -20 
o
C.  
 
Bacterial strains 
Five S. aureus strains were included in this study: the collection 
strain S. aureus CECT 976, used as the model microorganism 
for antimicrobial tests with phytochemical compounds;
16, 17
 S. 
aureus SA1199B, which overexpresses the NorA MDR efflux 
pump; S. aureus RN4220, which contains plasmid pU5054 (that 
carries the gene encoding the MsrA macrolide efflux protein); 
S. aureus XU212, which possesses the TetK efflux pump; and 
the clinical MRSA strain MJMC001, which was obtained from 
the Hospital Centre of Trás-os-Montes and Alto Douro, Vila 
Real (Portugal). Prior to use, each strain that had been kept at -
80 ºC was transferred onto Mueller-Hinton (MH, Merck 
Milllipore, Germany) agar plate, grown overnight, and 
inoculated into MH broth at 37 
o
C and under agitation (150 
rpm). 
 
Antibiotics and other chemicals  
The antibiotics: ampicillin, ciprofloxacin, erythromycin, 
oxacillin and tetracycline, were obtained from Sigma-Aldrich 
(St. Louis, Missouri, EUA) and prepared according to the 
Clinical and Laboratory Standards Institute (CLSI) guidelines.
2
 
Betulinic acid, lupeol, betulin, hederagenin, ursolic acid and 
oleanolic acid were purchased from Sigma-Aldrich and their 
stock solutions (1 g L
-1
) were prepared in dimethyl sulfoxide 
(DMSO). 
 
Antibacterial susceptibility testing 
Before testing, the dried MeOH extracts were prepared in 
DMSO. The MIC of each plant extract was determined by 
microdilution technique according to the CLSI guidelines 
2
. 
Bacteria (~10
6
 CFU mL
-1
) were inoculated into MH broth and 
200 μL well
-1
 were dispensed in 96-well microtiter plates, along 
with 2-fold dilutions of the MeOH extracts. The highest 
concentration tested for each plant extract was 4 g L
-1
. Plant 
extracts did not exceed 5% (v/v) of the volume of the well. MIC 
was defined as the lowest concentration of the extract that 
inhibited bacterial growth after 24 h of incubation at 37 ºC. 
The bacterial growth was determined at 600 nm using a 
microplate reader (Spectramax M2e, Molecular Devices, Inc., 
Sunnyvale, USA). The highest concentration of DMSO 
remaining after dilution (5% (v/v)) caused no inhibition of 
bacterial growth (data not shown). Three independent 
experiments were performed for each plant extract.  
 
Antibiotic-potentiation testing – Disc diffusion test 
Disc diffusion test is the most suitable technique for plant 
extracts, since allows adequate visualization and detection of 
the potentiating effects as evidenced in diverse studies.
16, 17
 
Plant extracts showing no MIC below 4 g L
-1
 were tested for an 
antibiotic-potentiating activity at several concentrations 
(between 0.125 to 4 g L
-1
), in order to define the 
minimal/optimal concentration causing antibiotic potentiation. 
Each extract prepared in DMSO was added to MH agar (after 
autoclaved and cooled) yielding the final concentration 
desired. Plant extracts did not exceed 5% (v/v) of the total 
volume of medium. Then 20 mL of medium was poured into 90 
mm Petri dishes. The bacterial suspensions were adjusted to 
0.5 McFarland standards and seeded over hardened MH agar 
Petri dishes using a sterilized cotton swab. Sterile blank discs (6 
mm diameter; Oxoid) were placed on the agar plates. Ten µL 
of each antibiotic prepared according to the CLSI guidelines
2
 
(ampicillin – 10 µg disc
-1
; ciprofloxacin – 5 µg disc
-1
; 
erythromycin – 15 µg disc
-1
; tetracycline – 30 µg disc
-1
; and 
Page 2 of 14RSC Advances
R
S
C
A
dv
an
ce
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
29
 S
ep
te
m
be
r 2
01
6.
 D
ow
nl
oa
de
d 
by
 C
or
ne
ll 
U
ni
ve
rs
ity
 L
ib
ra
ry
 o
n 
30
/0
9/
20
16
 0
3:
50
:4
5.
 
View Article Online
DOI: 10.1039/C6RA21137B
RSC Advances  ARTICLE 
This journal is © The Royal Society of Chemistry 2016 RSC Advances, 2016, 00, 1-9 | 3  
Please do not adjust margins 
Please do not adjust margins 
oxacillin – 1 µg disc
-1
) was added to the blank discs. Discs with 
antibiotics were also applied on plant-free MH agar plates, as 
well as discs with DMSO (negative control). No inhibition zone 
was obtained with DMSO (data not shown). The plates were 
incubated at 37 
o
C for 24 h. After incubation, all the inhibition 
zone diameters (IZD) were recorded. On simple MH plates, 
antibiotic IZDs were analysed and strains were characterized 
for their susceptibility/ resistance profile to each antibiotic 
according to CLSI guidelines.
2
 The IZDs obtained in the plates 
containing the plant extract (IZDantib.+plant) were compared to 
the single antibiotic IZDs (IZDantib.). The antibiotic-potentiating 
activity of each plant extract was categorized into three 
classes: indifferent/no potentiation (+): (IZDantib. +plant – IZDantib.) 
< 4 mm; low potentiation/additive effect (++): 4 ≤ (IZDantib. +plant 
– IZDantib.) < 6 mm; and potentiation effect (+++): (IZDantib. +plant 
– IZDantib.)  ≥ 6 mm of inhibition of growth of S. aureus.
16, 17
 All 
tests were performed in triplicate in three independent 
experiments. 
 
Antibiotic-potentiation testing – Checkerboard 
The checkerboard assay was performed in order to assess the 
synergy between antibiotics and those phytochemicals with 
antibacterial activity. This method was performed according to 
CLSI guidelines
18
 as described in previous studies.
16, 17
 Both 
compounds yielded final concentrations between 2 × MIC to 
1/64 × MIC. Combinations did not exceed 5% (v/v) of the 
volume used in each well (200 µL). Growth controls consisted 
in 5% (v/v) DMSO. Incubation was performed for 24 h at 37 
o
C 
and readings were determined spectrophotometrically at 600 
nm. All MIC determinations were performed in triplicate. 
Antibiotic (A) + phytochemical (B) interactions were classified 
using the fractional inhibitory concentration (FIC) index: FICI = 
FIC(A) + FIC(B), where FIC(A) is the ratio between the MIC of 
drug A in combination and the MIC of drug A alone and FIC(B) 
is the ratio of the MIC of drug B in combination and the MIC of 
drug B alone.
19
 A FICI value of ≤ 0.5 was interpreted as 
synergy, > 4 as antagonism and > 0.5 – 4 as indifferent. 
 
Biofilm control experiment 
B. sempervirens was chosen for its promising antibiotic-
potentiating activity and evaluated for its ability to control 
(remove and inactivate) biofilms of S. aureus CECT 976 within 1  
h exposure. Biofilms were developed according to a modified 
microtiter plate test as described previously.
20
 Overnight 
cultures (~10
6
 cells mL
-1
) were added to sterile 96-well 
polystyrene microtiter plates (Orange Scientific, USA) to form 
biofilms at 37 
o
C and stirring at 150 rpm for 24 h. Afterwards, 
the medium was removed and the biofilms were exposed to 
the antibiotics and to the plant extract individually and in 
combination at 37 
o
C and stirring at 150 rpm for 1 h. Antibiotic 
solutions were applied at MIC and 50 × MIC against biofilms. 
The MeOH extract of B. sempervirens was applied at 
concentrations ranging from 0.05 to 5 g L
-1
. Drug combinations 
did not exceed 5% (v/v) of the well (200 µL). After incubation, 
biofilms were washed twice with saline solution (0.85% NaCl), 
scrapped and diluted for colony forming units (CFU) counting. 
The numbers of CFU per unit of adhesion area (CFU cm
-2
) were 
assessed in MH agar. Reduction (%) of the number of CFU cm
-2
 
(compared with DMSO growth control) was also assessed. 
 
Fractionation of active extract of Buxus sempervirens 
B. sempervirens leaves (160 g) were extracted with 500 mL of 
MeOH following the process described above. The MeOH 
extract was taken to dryness and redissolved in 225 mL of 
H2O/MeOH (4:1) and successively partitioned with 3 × 112.5 
mL of CHCl2 and n-BuOH, respectively. All the fractions were 
analyzed by 
1
H NMR and tested for both antibacterial and 
antibiotic-potentiating activities. Afterwards, the n-BuOH 
fraction (1.2 g) was further submitted to phytochemical 
investigation. The n-BuOH fraction was subjected to medium 
pressure liquid chromatography (MPLC, Sepacore, Büchi, 
Switzerland) in a silica gel column (80 g, 200 × 35 mm, i.d, 
Büchi), eluted with a gradient of CHCl3 (A): MeOH + HOAc 2% 
(B) as follow: 10% B for 15 min; linear increase 10-30% B in 5 
min; isocratic elution using 30% B for 20 min; linear increase 
30-50% B in 5 min, and finally 50% B for 10 min. The flow rate 
was 20 mL min
-1
 and the analysis was monitored by UV 
spectrometer at 220, 254, 280 and 365 nm. Collection was 
performed by volume were each fraction contained 20 mL, 
totalizing 53 fractions. The fractions were analyzed by 
analytical TLC and combined into 8 subfractions. TLC was 
performed using silica gel TLC plates (Merck, Darmstadt, 
Germany) with CHCl3:MeOH:HOAc (7.5:2.5:0.2). These eight 
fractions were analysed by 
1
H NMR and for their antibacterial-
potentiating analysis. 
 
NMR analysis  
Five hundred microliters of CH3OH-d4 were added to dried 
samples, and the resultant mixtures were vortexed for 10 s 
and sonicated for 20 min at 42 kHz, followed by centrifugation 
at 13000 rpm at room temperature for 5 min. Three hundred 
microliters of the supernatant were transferred to a 3 mm 
micro-NMR tube and analysed. 
1
H NMR spectra were recorded 
at 25 
o
C on a 600 MHz Bruker DMX-600 spectrometer (Bruker, 
Karlsruhe, Germany) operating at a proton frequency of 
600.13 MHz. MeOH-d4 was used as the internal lock. 
1
H NMR 
experimental parameters were the following: 128 scans 
requiring 10 min and 26 s acquisition time, 0.16 Hz point
-1
, 
pulse width (PW) = 30° (11.3 μs), and relaxation delay 
(RD) = 1.5 s. FIDs were Fourier transformed with LB = 0.3 Hz. 
The resulting spectra were manually phased and baseline 
corrected, and calibrated to residual CH3OH-d4 at 3.3 ppm, 
using TOPSPIN 3.2 software (Bruker BioSpin GmbH, 
Rheinstetten, Germany).  
 
Statistical analysis 
For statistical analysis, the in vitro results were analysed by 
Student’s t test using the statistical program SPSS version 19.0 
(Statistical Package for the Social Sciences). Statistical 
calculations were based on a confidence level ≥ 95% (P < 0.05) 
which was considered statistically significant.  
Results and Discussion 
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Regardless of their medicinal uses, all plants have their own 
defence mechanisms from pathogens, producing a wide range 
of different chemicals for that purpose. In this study, twenty-
eight plants were assessed for their activity for potentiating 
antibiotics against diverse S. aureus strains. The plants were 
selected among different families in order to be able to test a 
large variety of extracts and metabolites. Table 1 describes the 
plants tested in this study as well as their 
ethnopharmacological relevance. The MIC for all MeOH 
extracts was determined for concentrations below 4 g L
-1
. Only 
four plant extracts showed a detectable MIC (Table 2). 
Eucalyptus globulus presented the highest antibacterial activity 
with a MIC between 0.125 and 0.25 g L
-1
 against the diverse S. 
aureus strains, including MRSA. This activity is in accordance 
with its therapeutic use.
1
 Other studies reported that the 
essential oils from the leaves and the flowers of E. globulus 
inhibited the growth of Escherichia coli, S. aureus,
21
 MRSA and 
vancomycin-resistant enterococci (VRE) Enterococcus 
faecalis.
22
 Concerning the other antibacterial plants, previous 
studies corroborate the results obtained: Basile, et al.
23
 found 
MIC in the range of 64–0.256 g L
-1
 of the aqueous extract of 
Castanea sativa (pH 3.0) against several bacteria including S. 
aureus; Agrimonia eupatoria was reported for its inhibitory 
effects against S. aureus;
24-26
 other authors reported 
antibacterial activity of n-hexane and CHCl2 extracts of 
Fraxinus excelsior against S. aureus  (MIC of 0.125 and 0.25 g L
-
1
, respectively) and MRSA strains (MIC of 0.5 and 1.0 g L
-1
, 
respectively).Middleton, et al.
27
 
The plant extracts that did not show any detectable 
antibacterial activity were further evaluated for antibiotic-
potentiating activity with five antibiotics by the disc diffusion 
method. First, the classification of S. aureus strains according 
to their resistance profile was performed based on the 
comparison of the MICs/IZDs results and the susceptibility 
breakpoints of CLSI guidelines,
2
 as shown in Table 3. Table 4 
shows the antibiotic-potentiation results obtained for each 
plant extract. Only plant extracts showing potentiation of at 
least one antibiotic were included. No IZD originated by the 
combinations between plant extracts and antibiotics was ever 
inferior to that promoted by the antibiotic alone (P > 0.05). 
Plants promoting antibiotic-potentiation were: plants from 
Rosaceae family, including all Prunus spp. and Pyrus communis, 
Acacia dealbata, both Asteraceae plants, Centaurea nigra and 
Eupatorium cannabium, as well as Buxus sempervirens.  
Prunus spp. MeOH extracts showed interesting 
potentiating results though only at high concentrations (4 g L
-
1
). Results were very similar between the three plant extracts. 
Potentiation/additive effects were mainly found with 
ciprofloxacin against SA1199B strain, tetracycline against CECT 
976 and erythromycin against CECT 976, RN4220 and 
MJMC001. No study about antibiotic-potentiating activity of 
these Prunus species was previously reported. The MeOH leaf 
extracts from A. dealbata (at 2 g L
-1
) potentiated ciprofloxacin 
against S. aureus CECT 976 and SA1199B and erythromycin 
against strains CECT 976, RN4220 and MJMC001 (only additive 
interactions were obtained against these last two strains). 
Taguri, et al.
28
 found generally weak activity of A. dealbata 
extract against many different bacteria while Olajuyigbe and 
Afolayan
29
 found synergistic interactions between Acacia 
mearnsii and erythromycin, metronidazole, amoxicillin, 
chloramphenicol and kanamycin against S. aureus. Other 
Table 1 List of the plants tested in this study and their 
ethnopharmacological relevance
1
 
 Plant name 
Common 
name 
Family Class.* 
1 Acacia dealbata Mimosa Fabaceae - 
2 Genista tridentata Carqueja Fabaceae - 
3 Prunus domestica Plum Rosaceae 2 
4 Prunus avium Wild cherry Rosaceae 2 
5 Prunus persica Peach tree Rosaceae 3 
6 Pyrus communis Pear tree Rosaceae 1 
7 Agrimonia eupatoria Church Steeples Rosaceae 3 
8 Eriobotrya japonica loquat Rosaceae 3 
9 Crataegus monogyna Hawthorn Rosaceae 5 
10 Rubus idaeus Wild Raspberry Rosaceae 3 
11 Malus communis Apple tree Rosaceae 2 
12 Eupatorium 
cannabinum 
Hemp agrimony Asteraceae 3 
13 Centaurea nigra Black knapweed Asteraceae 2 
14 Physalis angulata Cutleaf Ground-
cherry. 
Solanaceae 1 
15 Cyphomandra betacea Tree tomato Solanaceae - 
16 Nerium oleander Oleander Apocynaceae 2 
17 Trachelospermum 
jasminoides 
Star jasmine Apocynaceae 2 
18 Eucalyptus globulus Blue Gum Tree Myrtaceae 4 
19 Calluna vulgaris Calluna Ericaceae 2 
20 Ficus carica Fig tree Moraceae 2 
21 Castanea sativa Sweet chestnut Fagaceae 2 
22 Juglans regia Walnut Juglanduceae 3 
23 Diospyros kaki Japanese 
Persimmon 
Ebenaceae 3 
24 Vitis vinifera Grape Vine Vitaceae 2 
25 Fraxinus excelsior European ash Oleaceae 2 
26 Actinidia chinensis Chinese 
gooseberry 
Actinidiaceae 2 
27 Buxus sempervirens Common box Buxaceae 2 
28 Pteridium aquilinum Bracken Polypodiaceae 2 
Table 2 MIC ranges (g L
-1
) for the MeOH extracts that exhibited 
antibacterial activity against the S. aureus strains for concentrations 
lower than 4 g L
-1 
 
 Plant  
MIC  
( ) 
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MeOH extracts showed significant activities: C. nigra (at 1 g L
-1
) 
potentiated ciprofloxacin against CECT 976 and SA1199B and 
erythromycin against CECT 976; E. cannabium (at 1 g L
-1
) 
potentiated tetracycline against strain CECT 976, and 
erythromycin against CECT 976, RN4220 and MJMC001; P. 
communis (at 4 g L
-1
) potentiated tetracycline and 
erythromycin against CECT 976; and F. carica (at 2 g L
-1
) 
potentiated ciprofloxacin against SA1199B. B sempervirens (at 
0.5 g L
-1
) promoted several additive and potentiating effects 
when combined with all antibiotics against CECT 976; with 
ciprofloxacin against SA1199B and erythromycin against 
strains RN4220 and MJMC001.  
Ciprofloxacin, erythromycin and tetracycline were 
potentiated by the plant extracts mentioned even against 
MRSA. Resistance to these antibiotics can be easily achieved 
with the expression of efflux pumps from pathogens.
30
 Most of 
these plant extracts may be causing efflux pump inhibition in S. 
aureus, thus explaining the potentiation of ciprofloxacin, 
tetracycline and erythromycin. Indeed, the number of plant 
extracts producing efflux pump inhibitors seems to be 
considerable, as it is being extensively reported.
9, 10, 31, 32
 No 
plant extract significantly potentiated β-lactam antibiotics, but 
additive effects were found with B. sempervirens. Therefore, B. 
sempervirens seems to act as a general potentiator for the 
several antibiotics, regardless the antibiotic class. Thus, it is 
possible that a mechanism, not efflux pump related, is 
inhibited by B. sempervirens extract.  
Antibiotic potentiation can be reached by compounds that 
are interfering with other mechanisms of the bacterial cell that 
not involve drug resistance mechanisms, such as quorum-
sensing, virulence activation, biofilm formation, adherence to 
the host tissues,
33
 etc. Bacterial biofilms are particularly 
problematic since they become even more resistant to most 
available antibiotics. Any effective strategy able to impair 
biofilm formation or disturb, weaken or disperse its structure 
is urgently needed and for long desired. The MeOH extract of 
B. sempervirens was analyzed for its ability to control biofilms 
of the susceptible strain S. aureus CECT 976, against which the 
antibiotic combinations with B. sempervirens extract were 
generally more effective.  
The MeOH extract of B. sempervirens was evaluated 
against CECT 976 24 h-old biofilms at several concentrations 
(Fig. 1). It is possible to observe an overall concentration-
dependent effect, and increasing concentrations of B. 
sempervirens extract caused high biofilm removal (P < 0.05), 
except for 0.25 g L
-1
 and 5 g L
-1
, which did not show 
Table 3 Susceptibility profiles of S. aureus strain tested in this study: 
IZDs (mm) and MICs (mg L
-1
) for each antibiotic and strain are 
represented. Strains were characterized as resistant (R), intermediate 
(I) or susceptible (S) to each antibiotic according to CLSI guidelines
2
 
 
 CECT 976 SA1199B* XU212* RN4220* MJMC001 
AMP IZD  36.0 ± 1.0    0.0 ± 0.0 
MIC 1.5 - - - 64 
Class. S    R 
OXA IZD 39.7 ± 0.6    0.0 ± 0.0 
 MIC 0.48 - - - 128 
 Class. S    R 
CIP IZD 33.3 ± 0.6 13.0 ± 0.0   0.0 ± 0.0 
 MIC 1 4 - - 256 
 Class. S R   R 
TET IZD 23.7 ± 0.6  9.0 ± 1.0  26.0 ± 0.0 
 MIC 0.96 - 32 - 0.5 
 Class. S  R  S 
ERY IZD 26.3 ± 0.6   0.0 ± 0.0 12.5 ± 0.6 
 MIC 0.24 - - 256 96 
 Class. S   R R 
 
Table 4 Results obtained by disc diffusion method for the combination between the selected antibiotics and the plant MeOH extracts against the S. 
aureus strains. The antibiotic-potentiating activity of each plant extract was categorized into three classes: indifferent (+), additive (++) and 
potentiation (+++). The concentrations described for each plant extract are the minimal/optimal concentrations causing potentiation of the antibiotics. 
Only the plant extracts that potentiate at least one antibiotic are represented. No antagonistic interactions between antibiotics and plant extracts 
were obtained 
 
 
 CECT 976 SA1199B* XU212* RN4220* MJMC001 
Plant  AMP OXA CIP TET ERY CIP TET ERY AMP OXA CIP TET ERY 
Acacia dealbata 2 + + +++ + +++ +++ + ++ + + + + ++ 
Pyrus communis 4 + + + +++ +++ + ++ + + + + + + 
Prunus avium 4 + + + +++ +++ +++ ++ +++ + + + + ++ 
Prunus domestica 4 + + + +++ +++ +++ ++ +++ + + + + ++ 
Prunus persica 4 + + ++ +++ ++ +++ ++ +++ + + ++ + ++ 
Centaurea nigra 1 + + +++ + +++ +++ + + + + + + + 
Eupatorium cannabinum 1 + + + +++ +++ + + +++ + + + + +++ 
Ficus carica 2 + + + ++ + +++ + + + + + + + 
Buxus sempervirens 1 ++ ++ +++ +++ +++ +++ + +++ + + + + +++ 
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improvement over the preceding concentrations of 0.1 and 1 g 
L
-1
, respectively (P > 0.05). The minimal concentration causing 
potentiation with planktonic cells (1 g L
-1
) was the one causing 
the highest biofilm CFU control (88%). Additionally, 
combinations between B. sempervirens MeOH extract with 
ciprofloxacin, tetracycline and erythromycin against 24 h-old 
biofilms were assessed (Fig. 2). Antibiotics were applied at MIC 
and 50 × MIC and the extract of B. sempervirens was applied at 
the concentration causing highest biofilm removal/inactivation 
(1 g L
-1
). Concerning the single activity of the antibiotics at MIC, 
ciprofloxacin, tetracycline and erythromycin promoted a 
biofilm CFU control of 38, 31 and 21%, respectively. Antibiotic 
applied at 50 × MIC did not show any improvement over 
application at MIC for ciprofloxacin and erythromycin (P > 
0.05). Tetracycline at 50 × MIC did not cause any biofilm 
control (similar CFU cm
-2
 values to the growth control, P > 
0.05). This supports the concept of how bacteria are much 
more protected within a biofilm.
34
 Comparing individual 
activities, B. sempervirens MeOH extract surprisingly achieved 
the best ability to control S. aureus CECT 976 biofilms within 1 
h of application, even not showing antibacterial activity at this 
concentration. This proposes the potential of B. sempervirens 
extract to disperse biofilms without causing antimicrobial 
effects. According to Monzón et al.
35
 it is possible to classify a 
combination between a plant extract/phytochemical and an 
antibiotic as synergic if the log10 reduction CFU cm
-2
 caused by 
the combination is significantly higher (P < 0.05) than the sum 
of reductions of individual treatments. In this case, the 
application of antibiotics at MIC did not promote any 
significant improvement over activity of the plant extract alone 
(P > 0.05).  
Afterwards, B. sempervirens MeOH extract was submitted 
to fractionation for the identification of the bioactive 
compounds. Among the subfractions obtained from the n-
BuOH fraction of B. sempervirens, through silica gel column, F1 
and F2 were differentiated, showing antibiotic-potentiating 
activity (at 0.5 g L
-1
, data not shown). Analysing the 
1
H NMR for 
all the eight fractions obtained, it was possible to compare the 
spectra of the active fractions F1 and F2 with the non-active 
ones. Bearing in mind the similar activity, some signals were 
found in both fractions (Fig. 3), which were not found in the 
non-active ones. The identification was carried out using our 
in-house library of NMR data of common metabolites. Based 
on characteristic methyl and olefinic signals it was possible to 
identify betulinic acid (Fig. 4) as a major component together 
with oleanane and ursane type terpenoids. Betulinic acid and 
other similar terpenoids − lupeol, betulin, hederagenin, ursolic 
acid and oleanolic acid − were tested for their antibacterial 
activity by microdilution technique as previously explained. 
Pentacyclic triterpenoids α-amyrin, betulinic acid and 
betulinaldehyde, and other related triterpenes such as 
imberbic acid, oleanolic acid, ursolic acid, ulsolic acid, rotundic 
acid and zeylasteral have been reported to possess 
antimicrobial activity against many bacterial species, especially 
Gram-positive, but also against Gram-negative.
36, 37
 In this 
study, only oleanolic acid and ursolic acid showed MIC up to 
120 mg L
-1
, which was 62.5 and 15.6 mg L
-1
, respectively, 
against S. aureus CECT976.  After MIC determination, these 
terpenoids were evaluated in combination with antibiotics 
searching for a synergistic activity through checkerboard 
method (Table 5). Analysing the FICI values, it is possible to 
detect synergism only between oleanolic acid with 
erythromycin and tetracycline (FICI ≤ 0.5) and between ursolic 
acid and tetracycline (FICI = 0.31) against S. aureus CECT 976. 
Similarly,  Fontanay, et al.
38
 found MIC for ursolic acid and 
oleanolic acid of 8 and 32-64 mg L
-1
 against S. aureus 
ATCC25923 and ATCC29213 but not for betulinic acid. No MIC 
was found against one MRSA strain.
38
 Contrarily, in other study, 
oleanolic acid was reported to inhibit MRSA with a MIC 
between 16 and 128 mg L
-1
 
39
 and to synergize with ampicillin 
against S. aureus.
40
 Chung, et al.
36
  showed that betulinic acid 
and similar compounds, α-amyrin and betulinaldehyde, 
inhibited methicillin-susceptible S. aureus (MSSA) and MRSA 
(MIC between 64 and 512 mg L
-1
), and synergized with 
methicillin and vancomycin against the same strains. 
Therefore, it seems that the antibacterial and synergistic 
activities of triterpenoids vary widely, not only between 
susceptibility methods, but also between strains belonging to 
the same species. Considering the low activity displayed by 
betulinic acid, which was found in the active fractions of B. 
sempervirens, other triterpenoids also existing in this plant, as 
reported for example by Abramson, et al.
41
, or other sterols, 
alkaloids and anthocyanins that are typical of Buxus spp.
42
, 
could synergistically contribute to the antibiotic-potentiation 
and anti-biofilm effects displayed by this plant. Further 
isolation of the active fractions of the plant towards the 
identification of all the involved metabolites is apparently 
necessary. 
Triterpenoids are widely distributed in the plant kingdom 
and their therapeutic activities (such as antibacterial, antiviral, 
antiulcer, anti-inflammatory and anticancer) have been 
described in numerous reports. Plenty studies were also 
initiated to identify the cellular targets and molecular 
mechanisms of triterpenoids. Besides their influence on 
bacterial gene expression,
43
 cell autolysis and peptidoglycan 
turnover,
37
 oleanolic acid and related compounds also seem to 
affect the formation and maintenance of biofilms.
44
 Indeed, 
Table 5 MIC fold reductions obtained with the combination between the 
antibiotics with oleanolic acid and ursolic acid. FICI values are determined 
for each combination. Classification of the combination is given as 
synergism (S) or indifference (I) 
 
 Antibiotic - 
Oleanolic acid 
Antibiotic - 
Ursolic acid 
 MIC fold 
reduction 
MIC fold 
reduction 
FICI* 
MIC fold 
reduction 
MIC fold 
reduction 
FICI* 
AMP 2 2 1 (I) 2 2 1 (I) 
CIP 4 2 0.75 (I) 8 2 0.63 (I) 
TET 4 4 0.5 (S) 4 16 0.31 (S) 
ERY 8 4 0.38 (S) 2 2 1 (I) 
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terpenes are believed to influence the fatty acid composition 
of the cell membrane, and thus cell hydrophobicity, which can 
lead to biofilm eradication.
45
 To confirm this, oleanolic acid, 
which caused the best antibiotic-potentiation in this study, 
was evaluated for its anti-biofilm activity against S. aureus 
CECT 976 biofilms. Fig. 5 shows the number of CFU cm
-2
 
obtained after 1h exposure to oleanolic acid at ½ MIC, MIC and 
2 × MIC as well as with antibiotics at MIC, individually and in 
combination. Oleanolic acid applied at ½ MIC, MIC and 2 × MIC 
caused high biofilm CFU reduction, 70, 81 and 85%, 
respectively. The combination between the antibiotics and 
oleanolic acid never promoted higher biofilm reductions than 
those obtained with oleanolic acid alone. The exception was 
the combination of ciprofloxacin (at MIC) with oleanolic acid 
(at ½ MIC), that showed to be significantly than oleanolic acid 
alone at the same concentration (82%, P < 0.05). However, 
diverse combinations achieved worst biofilm reductions than 
those obtained with oleanolic acid alone (P < 0.05): between 
oleanolic acid and erythromycin, between oleanolic acid (at 
MIC) and tetracycline (at MIC) and between oleanolic acid (at 2 
× MIC) and ciprofloxacin (at MIC).  
One could expect that by combining antibiotics with a 
possible biofilm inhibitor, the outcome would be an improved 
therapeutic benefit. Nevertheless, probably by applying the 
combination in a preliminary stage of bacteria 
adhesion/biofilm formation, the combinations would be more 
effective, which would explain the potentiation observed. 
Kurek, et al. (2012)
40
 also found synergistic antibacterial 
effects of oleanolic acid in combination with ampicillin 
against biofilms of S. aureus and S. epidermidis, and with 
oxacillin against biofilms of L. monocytogenes, S. epidermis and 
S. aureus. Ursolic acid was found to inhibit biofilm formation of 
MRSA by reducing amino acids metabolism and expression of 
adhesins,
46
 to induce genes related to chemotaxis, mobility 
and heat shock response, and to repress genes that have 
functions in cysteine synthesis and sulfur metabolism.
47
  
Conclusions 
Restoring the activity of antibiotics that were already accepted 
and approved for clinical safety aspects, minimal toxicity and 
side effects, could thereby potentially reduce the costs 
associated to drug preclinical and clinical development. This 
strategy is possible by combining antibiotic with adjuvants that 
are able to inhibit drug-resistance mechanisms expressed by 
the pathogens. This study allowed to assess the potential of 28 
different plant species to be used in co-therapies against S. 
aureus, a major cause of hospital acquired infections. From the 
tested plants, four (E. globulus, C. sativa, A. eupatoria and F. 
excelsior) were found to have antibacterial activity, being in 
agreement with their traditional uses, and nine (A. dealbata, P. 
communis, P. avium, P. domestica, P. persica, C. nigra, E. 
cannabinum, F. carica, B. sempervirens) were able to 
potentiate antibiotic activity, especially ciprofloxacin, 
tetracycline and erythromycin. Additionally, this study 
highlights the potential of B. sempervirens extract, and 
particularly of triterpenoids for their relevant ability to act 
against S. aureus biofilms. Nevertheless, besides betulinic acid, 
the major triterpenoid found in the active fractions of B. 
sempervirens, other relevant molecules may contribute to the 
antibiotic-potentiation and anti-biofilm effects exhibited by the 
plant extract.  
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Fig. 1 CFU cm
-2
 of S. aureus CECT 976 biofilms after 1 h exposure to MeOH extract of B. 
sempervirens (BS) at 0.05, 0.1, 0.25, 1 and 5 g L-1. Percentage of biofilm CFU reduction is also 
presented for each assay. (*) when statistically lower than the growth control (GC, 5% v/v 
DMSO), (P < 0.05); (**) when statistically different from GC and from the preceding 
concentration.  
 
Fig. 2 CFU cm
-2
 of S. aureus CECT 976 after 1 h exposure to antibiotics and the MeOH of B. 
sempervirens individually and combined. Percentage of biofilm CFU reduction is also presented 
for each assay. The antibiotics ciprofloxacin (CIP), tetracycline (TET) and erythromycin (ERY) 
were applied at MIC and 50 × MIC. B. sempervirens (BS) was applied at 1 g L
-1
 (optimal 
concentration promoting antibiotic potentiation and biofilm reduction/inactivation). (*) when 
statistically different from growth control (GC, 5% v/v DMSO), (P < 0.05).  
 
Fig. 3 1H-NMR spectra (0.4 – 5.0 ppm) of the fractions (F1 – F8) obtained from n-BuOH 
fraction of B. sempervirens; the numbering in the active fractions F1 and F2 is H-number of 
betulinic acid structure in Fig. 4 are resistant to: CIP, TET and ERY, respectively.  
 
Fig. 4 Chemical structure of betulinic acid. 
 
Fig. 5 CFU cm-2 of S. aureus CECT 976 biofilms after 1 h exposure to oleanolic acid (OA) and 
antibiotics, individually and combined. Percentage of biofilm CFU reduction is also presented 
for each assay. Oleanolic acid (OA) was applied at ½ MIC, MIC and 2 × MIC. The antibiotics 
ciprofloxacin (CIP), tetracycline (TET) and erythromycin (ERY) were applied at MIC. (*) when 
statistically different from the growth control (GC, 5% v/v DMSO), (P < 0.05); (**) when 
statistically different from the respective antibiotic applied individually.  
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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